WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555385
CAS#: 1629677-75-3 (free base)
Description: Zetomipzomib, also known as KZR-616, is a potent, selective dual immunoproteasome subunit LMP7/LMP2 inhibitor with IC50 of 39 nM/139 nM. KZR-616 is presently in clinical trials for treatment of rheumatic disease.
Hodoodo Cat#: H555385
Name: Zetomipzomib
CAS#: 1629677-75-3 (free base)
Chemical Formula: C30H42N4O8
Exact Mass: 586.30
Molecular Weight: 586.686
Elemental Analysis: C, 61.42; H, 7.22; N, 9.55; O, 21.82
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 2170983-62-5 (maleate) 1629677-75-3 (free base)
Synonym: KZR-616; KZR 616; KZR616; Zetomipzomib
IUPAC/Chemical Name: (2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide
InChi Key: GHYOCDFICYLMRF-UTIIJYGPSA-N
InChi Code: InChI=1S/C30H42N4O8/c1-19(31-24(35)17-34-12-14-41-15-13-34)28(38)33-25(26(36)21-8-10-22(40-3)11-9-21)29(39)32-23(16-20-6-4-5-7-20)27(37)30(2)18-42-30/h6,8-11,19,23,25-26,36H,4-5,7,12-18H2,1-3H3,(H,31,35)(H,32,39)(H,33,38)/t19-,23-,25-,26+,30+/m0/s1
SMILES Code: O=C(N[C@@H](CC1=CCCC1)C([C@]2(C)OC2)=O)[C@@H](NC([C@@H](NC(CN3CCOCC3)=O)C)=O)[C@H](O)C4=CC=C(OC)C=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 586.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, Moebius D, Kirk
C, McMinn DL. A required immunoproteasome subunit inhibition profile for
anti-inflammatory efficacy and clinical candidate KZR-616
((2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2
-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)pr
openamide). J Med Chem. 2018 Oct 31. doi: 10.1021/acs.jmedchem.8b01201. [Epub
ahead of print] PubMed PMID: 30380863.
2: Ogorevc E, Schiffrer ES, Sosič I, Gobec S. A patent review of immunoproteasome
inhibitors. Expert Opin Ther Pat. 2018 Jul;28(7):517-540. doi:
10.1080/13543776.2018.1484904. Epub 2018 Jun 14. Review. PubMed PMID: 29865878.
